

Special Issue

Mechanisms and Applications of Metformin in Human Diseases

Message from the Guest Editors

To encompass the remarkable breadth of ongoing investigation on metformin and aging-related diseases, research articles, short communications, review articles, as well as clinical studies covering a wide range of topics related to the therapeutic application of metformin (or metformin derivatives) in chronic diseases, hereditary genetic disorders, and rare diseases, in addition to T2D, such as chronic respiratory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, as well as viral infections, including SARS-CoV-2/COVID-19, will be welcomed in this Special Issue in *Pharmaceuticals*. We aim to include manuscripts, including but not limited to, metformin-centered molecular mechanisms, signaling pathways, metabolism, pre-clinical models, drug formulations, analogues, drug combinations, immune response, and clinical trials. With the manuscript compendium, we will generate a molecular-clinical map of the mechanisms by which metformin not only mitigates the drivers of aging diseases but also its ability to boost (or to prevent pathogenic disruption of) the organizational and dynamical hallmarks that maintain the physiological state in human health.

Guest Editors

Dr. Elisabet Cuyàs

1. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, 17005 Girona, Spain
2. Metabolism & Cancer Group, Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain

Dr. Javier A. Menendez

1. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, 17005 Girona, Spain
2. Catalan Institute of Oncology (ICO)-Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain

Deadline for manuscript submissions

closed (30 September 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/149824

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)